Education
About Us
Working with TipRanks
Follow Us
Pelthos Therapeutics Inc. (PTHS)
:PTHS
PTHS Stock Chart & Stats
$29.00
--
Market closed
$29.00
--
Day’s Range― - ―
52-Week Range$5.51 - $54.29
Previous CloseN/A
VolumeN/A
Average Volume (3M)23.37K
Market Cap
$81.67M
Enterprise Value$74.95M
Total Cash (Recent Filing)$14.25M
Total Debt (Recent Filing)$3.48M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 13, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,086,681
10 Day Avg. Volume22,072
30 Day Avg. Volume23,371
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)-2.55
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue10.12
Enterprise Value/Gross Profit18.63
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$63.00Price Target Upside117.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-18.09
Revenue Forecast (FY)$23.15M
Bulls Say, Bears Say
Bulls Say
Market Expansion And AccessibilityZelsuvmi has been added to the Medicaid formularies in New York, Texas, and Alabama without needing prior authorization, increasing its accessibility and potential sales volume.
Product Launch And Market EntryPTHS has successfully launched its first drug, Zelsuvmi, which is the only at-home treatment for molluscum contagiosum, targeting a large, underserved market.
Sales And Revenue GrowthThe commercial uptake of Zelsuvmi has exceeded expectations with a significant increase in prescriptions and stable channel inventory.
Bears Say
Competitive ThreatVerrica Pharmaceuticals poses a primary competitive threat to Zelsuvmi with its FDA-approved MC drug Ycanth, which offers a different application process and cost structure.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics Inc.’s price range in the past 12 months?
Pelthos Therapeutics Inc. lowest stock price was $5.51 and its highest was $54.29 in the past 12 months.
What is Pelthos Therapeutics Inc.’s market cap?
Pelthos Therapeutics Inc.’s market cap is $81.67M.
When is Pelthos Therapeutics Inc.’s upcoming earnings report date?
Pelthos Therapeutics Inc.’s upcoming earnings report date is Nov 13, 2025 which is 23 days ago.
How were Pelthos Therapeutics Inc.’s earnings last quarter?
Pelthos Therapeutics Inc. released its earnings results on Aug 18, 2025. The company reported -$5.38 earnings per share for the quarter, beating the consensus estimate of -$5.82 by $0.44.
Is Pelthos Therapeutics Inc. overvalued?
According to Wall Street analysts Pelthos Therapeutics Inc.’s price is currently Undervalued.
Does Pelthos Therapeutics Inc. pay dividends?
Pelthos Therapeutics Inc. does not currently pay dividends.
What is Pelthos Therapeutics Inc.’s EPS estimate?
Pelthos Therapeutics Inc.’s EPS estimate is -0.58.
How many shares outstanding does Pelthos Therapeutics Inc. have?
Pelthos Therapeutics Inc. has 3,086,681 shares outstanding.
What happened to Pelthos Therapeutics Inc.’s price movement after its last earnings report?
Pelthos Therapeutics Inc. reported an EPS of -$5.38 in its last earnings report, beating expectations of -$5.82. Following the earnings report the stock price went down -7.273%.
Which hedge fund is a major shareholder of Pelthos Therapeutics Inc.?
Currently, no hedge funds are holding shares in PTHS
Pelthos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
333.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5808.39%
Trailing 12-Months
Company Description
Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
PTHS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Pelthos' strong launch of ZELSUVMI and strategic growth plans, including a sales force expansion and acquisition of Xepi. However, the company faces challenges with high operating losses and uncertain long-term GTN levels. Overall, the positive aspects of strong revenue growth and strategic positioning outweigh the financial challenges.View all PTHS earnings summariesPTHS Stock 12 Month Forecast
Average Price Target
$63.00
▲(117.24% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―